{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}],"units":"Participants"}],"description":"Length of time from the date of first administration of study drug to the first evidence of disease progression or death, whichever is earlier","groups":[{"description":"E6201 240 mg/m\\^2 IV over 2 hours once weekly, on Days 1, 8, 15, and 22, repeated every 28 days (= 1 cycle) until progression of disease, toxicity or other reason for discontinuation of study drug, and followed for up to 6 months after the last dose.","id":"OG000","title":"E6201 240 mg/m^2 Weekly"},{"description":"E6201 320 mg/m\\^2 IV over 2 hours once weekly, on Days 1, 8, 15, and 22, repeated every 28 days (= 1 cycle) until progression of disease, toxicity or other reason for discontinuation of study drug, and followed for up to 6 months after the last dose.","id":"OG001","title":"E6201 320 mg/m^2 Weekly"},{"description":"E6201 160 mg/m\\^2 IV over 2 hours twice weekly, on Days 1, 4, 8, 11, 15, 18, 22 and 25, repeated every 28 days (= 1 cycle) until progression of disease, toxicity or other reason for discontinuation of study drug, and followed for up to 6 months after the last dose.","id":"OG002","title":"E6201 160 mg/m^2 Twice Weekly"},{"description":"E6201 240 mg/m\\^2 IV over 2 hours twice weekly, on Days 1, 4, 8, 11, 15, 18, 22 and 25, repeated every 28 days (= 1 cycle) until progression of disease, toxicity or other reason for discontinuation of study drug, and followed for up to 6 months after the last dose.","id":"OG003","title":"E6201 240 mg/m^2 Twice Weekly"},{"description":"E6201 320 mg/m\\^2 IV over 2 hours twice weekly, on Days 1, 4, 8, 11, 15, 18, 22 and 25, repeated every 28 days (= 1 cycle) until progression of disease, toxicity or other reason for discontinuation of study drug, and followed for up to 6 months after the last dose.","id":"OG004","title":"E6201 320 mg/m^2 Twice Weekly"}],"populationDescription":"The analysis population was the per-protocol set (PPS). The PPS included all subjects in the FAS who had a valid baseline and one or more post-treatment assessments for a specified measure.\n\nFor AML, MDS and CMML, progression was defined by relevant IWG criteria as failure to achieve at least a PR.\n\nNo responses; PFS could not be calculated.","reportingStatus":"POSTED","timeFrame":"From Cycle 1 Day 1 (C1D1) until death or study closure, up to 26 months","title":"Progression-Free Survival","type":"SECONDARY"}